Company shares are trading at $38.47 which is quite a bit above the 50 day moving average which is $34.44 and which is a tad above the 200 day moving average of $36.23. The 50 day moving average was up $4.03 and the 200 day average was up $2.24. (NASDAQ:MYL) shares saw light trading volume with 3,999K shares changing hands in the last trading session. Volume was down 13.51% under the stocks average daily volume.
Short traders are feeling a little more bearish on shares of Mylan N.V. lately if you look at the motion in short interest. The stock recorded a rise in short interest of 7.01% between September 15, 2017 and September 29, 2017. Short shares grew from 26,525,497 to 28,385,090 over that timeframe. The days to cover increased to 5.0 and the percentage of shorted shares is 0.05% as of September 29.
These firms have modified their investment in MYL. As of quarter end Oakbrook Investments LLC had sold 18,550 shares trimming its stake by 44.6%. The value of the total investment in Mylan N.V. decreased from $1,613,000 to $722,000 a change of 55.2% quarter over quarter. As of the end of the quarter Gateway Investment Advisers LLC had acquired a total of 37 shares growing its holdings by 0.1%. The value of the investment in (MYL) went from $1,113,000 to $900,000 a change of $213,000 since the last quarter.
State Treasurer State Of Michigan bolstered its holdings by buying 11,200 shares an increase of 7.4% as of 09/30/2017. State Treasurer State Of Michigan currently owns 162,709 shares valued at $5,104,000. The value of the position overall is down by 13.2%. As of quarter end Cutter & CO Brokerage, Inc. had acquired a total of 3,050 shares growing its position 13.3%. The value of the investment in Mylan N.V. went from $890,000 to $815,000 decreasing 8.4% for the reporting period.
August 7 investment analysts at Morgan Stanley maintained a stock rating of “Equal-Weight” and lowered the price expectation from $56.00 to $36.00. On August 16, 2017 the stock rating was changed to “Buy” according to a Citigroup report which was a boost from the previous “Neutral” rating.
On October 4 BTIG Research made no change to the company rating of “Buy” but moved down the price target to $45.00 from $85.00. October 6 investment analysts at Morgan Stanley held the company rating at “Equal-Weight” but raised the price target to $39.00 from $36.00.
The P/E ratio is currently 31.10 and market cap is 20.63B. As of the latest earnings report the EPS was $1.24 and is expected to be $4.58 for the current year with 536,280,000 shares outstanding. Analysts expect next quarter’s EPS will be $1.35 with next year’s EPS anticipated to be $5.32.
Mylan N.V., launched on July 7, 2014, is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Business’s Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment is primarily made up of its operations in the United States and Canada. The Europe segment is made up its operations in approximately 35 countries within the region. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand. Also included in the Rest of World segment are its operations in markets, which include countries in Africa (including South Africa), as well as Brazil and other countries throughout Asia and the Middle East. The Company conducts active pharmaceutical ingredient (API) business through Mylan Laboratories Limited (Mylan India). As of December 31, 2016, it offers product portfolios, including approximately 7,500 marketed products around the world, to customers in over 165 countries and territories. It operates a global vertically integrated manufacturing platform around the world and API operations. It also operates research and development (R&D) network that delivers product pipeline, including a range of dosage forms, therapeutic categories and biosimilars..